Fixing the broken healthcare investment model
The biotech model that worked so well for decades is all but played out. Innovative therapies that opened up new treatment horizons drove prices, and profits, higher. But, as they search for their next billion dollar products in promising growth areas such as speciality care – notably cancer and rare diseases – pharma companies must first answer a question: who will pay?
As pressure grows on healthcare systems from ageing and increasingly infirm populations, healthcare costs are already reaching nosebleed levels, rising from around 10 per cent of GDP a decade ago to 18 per cent in the USA1 and 14 per cent in Europe today. Payers and governments are accordingly querying and rejecting costly therapies resulting from recent R&D, or setting limits to how much they’ll pay for them, no matter how technologically advanced they might be.
“The old model of high innovation and the highest possible price tag is broken,” says Dr Nathalie Flury, co-head at the Global Equity Sustainable Healthcare Fund. “You have to find solutions with payers to come up with the optimal possible price; you have to price therapies in a way that makes sense at a health economic level.”
The experience of Bluebird Bio, which pulled its $1.8m per treatment rare disease therapy from European markets after failing to find buyers, serves as one recent, salutary lesson for life science companies and investors alike2.
Drastic price drops of almost two thirds of cholesterol-lowering PCSK9 inhibitors by such as Amgen and Sanofi in a bid to find a market in the US are another example, says Dr Michael Schröter, who is Flury’s Global Equity Sustainable Healthcare Fund co-head. “There’s not much talk about these drugs now.”
Other brand-new drugs surely cannot be sustained at current prices, such as the controversially approved new Alzheimers drug Aduhelm, at $56,000 per patient, a price which some estimates suggest could cost US Medicare $29bn a year. “Ten per cent of people over 65 are affected by Alzheimers in the US and would be eligible,” says Schröter. “A report by the Kaiser Family Foundation estimates that even if only one quarter of patients who currently use Alzheimers drugs were to take Aduhelm, it would mean Medicare would have close to double its Part B drug budget because of a single drug. It’s impossible.”
Comparable calculations apply across the Atlantic. “Everyone knows about rising healthcare costs, but people are much less aware of the consequences – especially so in Europe, where treatment is often provided by governments and citizens – and may not see what’s not being provided.”
French payers and the UK’s National Institute For Health and Care Excellence (NICE), for example, are declining to reimburse for several of the latest cancer therapies on cost grounds. Yet investors seem not to have woken up to the magnitude of this trend. “The pressure on health systems to change is something that has not sunk in yet; it is mainly hidden,” says Schröter.
Focusing on value
With healthcare budgets strained as never before, owing to even greater pressure arising from the pandemic, continued drug price escalation is even less viable. Investors would do well to take note of this mega trend. Focusing on clinical innovation and the theoretical market size for the resulting drugs is not enough. There’s a need to innovate on affordability, too, says Schröter. Companies seeking to simply maximise price and profit will not prosper in this new era if they do not address value.
This is the new imperative in healthcare, says Schröter, and one that he worked around while at Roche, where he was charged with tackling this very challenge as Head of Personalised Reimbursement Models. “We realised that just bringing therapies to market at maximum prices won’t work, yet you have to recover your investment. That was the impetus for me. This is an opportunity for investors to think ahead of where the industry is running.”
To pursue this opportunity, Schröter left Roche to team up with his old friend from university, then portfolio manager for Pictet Asset Management’s health fund, Dr Flury, to pursue this theme – and Viopas, a new boutique investment company, was born. The duo worked to develop proprietary tools and insights to help identify sustainable innovation from across a broad swath of the healthcare business, which taps into these new drivers in healthcare. They then joined HSBC Asset Management to head its newly launched fund.
The evidence is already clear, says Schröter. “We are seeing that companies with the right value proposition don’t face access restrictions, and their revenues go through the roof. It is a new environment. The sector is being turned upside down.”
- Capital loss risk: It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed
- Equity risk: Funds that invest in securities listed on a stock exchange or market could be affected by general changes in the stock market. The value of investments can go down as well as up due to equity markets movements
- Discretionary management risk: Discretionary management is based on anticipating the evolution of different markets and securities. There is a risk that the fund will not be invested at any time in the most efficient markets and securities
- Foreign Exchange risk: Where overseas investments are held, the rate of exchange of the currency may cause the value to go down as well as up. Variations in exchange rates between currencies can have a significant impact on the performance of the products presented
- Small & Mid cap risk: Please note that the fund is invested in securities issued by companies which, due to their small or mid-market capitalization, are less liquid and may present higher risks
This document is only intended for professional investors as defined by MIFID, in Switzerland by HSBC Asset Management (Switzerland) AG and is only intended for qualified investors in the meaning of Art. 10 para 3 of the Federal Collective Investment Schemes Act (CISA). All non-authorised reproduction or use of this commentary and analysis will be the responsibility of the user and will be likely to lead to legal proceedings. This document has no contractual value and is not by any means intended as a solicitation, nor an investment advice for the purchase or sale of any financial instrument in any jurisdiction in which such an offer is not lawful. The commentary and analysis presented in this document reflect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Asset Management (France). Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document.
If necessary, investors can refer to the complaints handling charter available in the banner of our website.
Please note that the distribution of the product can stop at any time by decision of the management company.
Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Capital is not guaranteed. It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed.
Past performance is no guarantee of future returns. Future returns will depend inter alia on market developments, the fund manager’s skill, the fund’s level risk and management costs and if applicable subscription and redemption costs. The return, the value of money invested in the fund may become negative as a result of price losses and currency fluctuations. There is no guarantee that all of your invested capital can be redeemed. Unless stated otherwise, inflation is not taken into account.
Synthetic Risk and Reward Indicator (SRRI): 6 out of 7. Do not run any unnecessary risk. Read the Key Investor Information Document. The fund invests in instruments of high level of volatility. The value of investments can go up as well as down. The rating is based on price volatility over the last five years, and is an indicator of absolute risk. Historical data may not be a reliable indication for the future. The scale varies from 1 (least risky) to 7 (most risky). The rating is not guaranteed to remain unchanged and the categorisation may shift over time. The lowest rating does not mean a risk-free investment. Do not run any unnecessary risk. Read the Key Investor Information Document.
Important information for Luxembourg investors: HSBC entities in Luxembourg are regulated and authorised by the Commission de Surveillance du Secteur Financier (CSSF).
Important information for Swiss investors: This document may be distributed in Switzerland only to qualified investors according to Art. 10 para 3, 3bis and 3ter CISA. The presented fund is authorised for distribution in Switzerland in the meaning of Art. 120 CISA. (Potential) investors are kindly asked to consult the latest issued Key Investor Information Document (KIID), prospectus, articles of incorporation and the (semi-)annual report of the fund which may be obtained free of charge at the head office of the representative: HSBC Asset Management (Switzerland) AG, Gartenstrasse26, P.O. Box, CH-8002 Zurich. Paying agent in Switzerland: HSBC Private Bank (Suisse) SA, Quai des Bergues9-17, P.O Box 2888, CH-1211 Genève 1.
HSBC GIF Global Equity Sustainable Healthcare is a sub fund of HSBC Global Investment Funds, a Luxemburg domiciled SICAV. Before subscription, investors should refer to Key Investor Document (KIID) of the fund as well as its complete prospectus. For more detailed information on the risks associated with this fund, investors should refer to the complete prospectus of the fund. The shares of HSBC Global Investment Funds have not been and will not be offered for sale or sold in the United States of America, its territories or possessions and all areas subject to its jurisdiction, or to United States Persons.
Any forecast, projection or target where provided is indicative only and is not guaranteed in any way.
Allocation is as at the date indicated, may not represent current or future allocation and is subject to change without prior notice.
These examples are historical and contains information that is not current and should not be construed as an advice, an offer to sell or solicitation of an offer to purchase or subscribe to any investment.
Swing pricing and Gates: Yes.
“Swing pricing” is a price adjustment mechanism intended to protect the unitholders, or shareholders, of a collective investment undertaking (UCI) against the transaction costs borne by this UCI due to new subscriptions or new buyouts. These transaction costs include, but are not limited to, broker commissions (for equities), the spread between the bid and ask prices (for interest rate products), taxes on financial transactions, fees transactions taken by the depositary, etc.
The fund has a redemption threshold (gate), the level at which the manager of an undertaking for collective investment in transferable securities can stagger the redemption of securities instead of proceeding immediately.
Article 8 SFDR =The product promotes environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices even if this is not its central point, or the central point of the investment process.
More information on our ‘Responsible Investment’ Policy and ‘Implementation Procedures’ can be found on our website. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus.
HSBC Asset Management is the brand name for the asset management business of HSBC Group. The above document has been produced by HSBC Asset Management (France) and has been approved for distribution/issue by the following entities:
HSBC Asset Management (France) - 421 345 489 RCS Nanterre. Portfolio management company authorised by the French regulatory authority AMF (no. GP99026) with capital of 8.050.320 euro, in Italy, Spain and Sweden through the Milan, Madrid and Stockholm branches of HSBC Asset Management (France), regulated respectively by Banca d’Italia and Commissione Nazionale per le Società e la Borsa (Consob) in Italy, the Comisión Nacional del Mercado de Valores (CNMV) in Spain and the Swedish Financial Supervisory Authority (Finansinspektionen) in Sweden. Offices: HSBC Asset Management (France)
Immeuble Coeur Défense - 110, esplanade du Général Charles de Gaulle - 92400 Courbevoie - La Défense 4 – France.
HSBC Asset Management (Switzerland) AG: Gartenstrasse 26, P.O. Box, CH-8002 Zurich. Paying agent: HSBC Private Bank (Suisse) S.A., Quai des Bergues 9-17, P. O. Box 2888, CH-1211 Geneva 1 In respect of the units distributed in Switzerland, the competent courts shall have exclusive venue at the registered office of the Representative in Switzerland. The official documents as per Art. 13a CISO as well as the (Semi-)Annual Report of the Fund may be obtained free of charge at the office of the Representative in Switzerland.
Non contractual document
Copyright : All rights reserved © HSBC Asset Management (France), 2021.